Literature DB >> 16755558

ADAMTS13 activity in sickle cell disease.

John-John B Schnog1, Johanna A Kremer Hovinga, Soraya Krieg, Sakir Akin, Bernhard Lämmle, Dees P M Brandjes, Melvin R Mac Gillavry, Fred D Muskiet, Ashley J Duits.   

Abstract

Sickle red blood cell (SRBC)-endothelial adhesion plays a central role in sickle cell disease (SCD)-related vaso-occlusion. As unusually large von Willebrand factor (ULVWF) multimers mediate SRBC-endothelial adhesion, we investigated the activity of ADAMTS13, the metalloprotease responsible for cleaving ULVWF multimers, in SCD. ADAMTS13 activity was determined using a quantitative immunoblotting assay. VWF:Ag and VWF:RCo were determined using commercial assays. The high-molecular-weight VWF multimer percentage was determined by employing gel electrophoresis. ADAMTS13 activity was similar among asymptomatic patients (n = 8), patients at presentation with a painful crisis (n = 23), and healthy controls. ADAMTS13/VWF:Ag ratios were lower in patients compared to healthy HbAA controls, with the lowest values at presentation with a painful crisis (P = 0.02). Division of samples in those with VWF:RCo/VWF:Ag ratios < 0.70 and those with ratios >or= 0.70 revealed significantly more samples with ratios >or= 0.70 (P = 0.01) collected during painful crises. ULVWF multimers were detected in 6 patient samples and in 1 control sample. ADAMTS13/VWF:Ag ratios were inversely related to the duration of symptoms at presentation with an acute vaso-occlusive event (r(s)-0.67, P = 0.002). Although SCD is characterized by elevated VWF:Ag levels, no severe ADAMTS13 deficiency was detected in our patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16755558     DOI: 10.1002/ajh.20653

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  17 in total

1.  What is behind a relapse of thrombotic thrombocytopenic purpura?

Authors:  Marco Capecchi; Andrea Artoni; Maria Domenica Cappellini; Giovanna Graziadei
Journal:  Intern Emerg Med       Date:  2017-11-02       Impact factor: 3.397

2.  The rate of hemolysis in sickle cell disease correlates with the quantity of active von Willebrand factor in the plasma.

Authors:  Junmei Chen; William E Hobbs; Jennie Le; Peter J Lenting; Philip G de Groot; José A López
Journal:  Blood       Date:  2011-02-07       Impact factor: 22.113

Review 3.  Role of the hemostatic system on sickle cell disease pathophysiology and potential therapeutics.

Authors:  Zahra Pakbaz; Ted Wun
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-18       Impact factor: 3.722

Review 4.  Pleiotropic effects of intravascular haemolysis on vascular homeostasis.

Authors:  Gregory J Kato; James G Taylor
Journal:  Br J Haematol       Date:  2009-12-01       Impact factor: 6.998

5.  Increased von Willebrand factor antigen and high molecular weight multimers in sickle cell disease associated with nocturnal hypoxemia.

Authors:  Suba Krishnan; Jamie Siegel; Gene Pullen; Megan Hevelow; Carlton Dampier; Marie Stuart
Journal:  Thromb Res       Date:  2008-01-29       Impact factor: 3.944

Review 6.  Coagulation abnormalities of sickle cell disease: Relationship with clinical outcomes and the effect of disease modifying therapies.

Authors:  Denis Noubouossie; Nigel S Key; Kenneth I Ataga
Journal:  Blood Rev       Date:  2015-12-24       Impact factor: 8.250

7.  Evaluation of von Willebrand factor and ADAMTS-13 antigen and activity levels in sickle cell disease patients in Kuwait.

Authors:  Anwar Al-Awadhi; Adekunle Adekile; Rajaa Marouf
Journal:  J Thromb Thrombolysis       Date:  2017-01       Impact factor: 2.300

8.  Plasma DNA is Elevated in Patients with Deep Vein Thrombosis.

Authors:  J A Diaz; T A Fuchs; T O Jackson; J A Kremer Hovinga; B Lämmle; P K Henke; D D Myers; D D Wagner; T W Wakefield
Journal:  J Vasc Surg Venous Lymphat Disord       Date:  2013-10-01

9.  Platelets in pulmonary vascular physiology and pathology.

Authors:  Michael H Kroll; Vahid Afshar-Kharghan
Journal:  Pulm Circ       Date:  2012-07       Impact factor: 3.017

10.  Role of extracellular hemoglobin in thrombosis and vascular occlusion in patients with sickle cell anemia.

Authors:  Zhou Zhou; Molly Behymer; Prasenjit Guchhait
Journal:  Anemia       Date:  2010-12-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.